Diagnostic and Prognostic Biomarkers for Malignant Mesothelioma: an Update

Overview

Journal Transl Lung Cancer Res

Date 2017 Jul 18

PMID 28713671

Citations 32

Authors

Zhongjian Chen

Giovanni Gaudino

Harvey I Pass

Michele Carbone

Haining Yang

Affiliations

Soon will be listed here.

Abstract

Malignant mesothelioma (MM) is an aggressive and lethal cancer, mostly related to inhalation of asbestos and erionite fibers. MM is associated with poor prognosis, because of its resistance to current therapies, even if higher survival occurs in patients diagnosed and treated when at stage I of the disease. However, these do not exceed 5% of the total number of cases, due to the inadequacy of the existing biomarkers for early and accurate diagnosis. Therefore, new effective biomarkers are needed for MM detection at earlier stages and to develop tailored therapies. Here we review the most promising biomarkers in MM to date: mesothelin, soluble mesothelin-related peptides (SMRPs), megakaryocyte potentiating factor (MPF), Osteopontin (OPN), Fibulin-3, high mobility group B1 (HMGB1), microRNAs (miRNAs), multiplex protein signatures. The validation of these biomarkers will allow their use, alone or in combination, for monitoring individuals from cohorts at risk of MM and attaining early detection of MM that is instrumental in improving patient survival.

Citing Articles

Unraveling Novel Strategies in Mesothelioma Treatments Using a Newly Synthetized Platinum(IV) Compound.

Favaron C, Gaiaschi L, Casali C, De Luca F, Gola F, Cavallo M Pharmaceutics. 2024; 16(8).

PMID: 39204360 PMC: 11359418. DOI: 10.3390/pharmaceutics16081015.

Expression of stathmin in asbestos-like fibers-induced mesothelioma: A preliminary report.

Lombardo C, Broggi G, Vitale E, Ledda C, Loreto C, Matera S Histol Histopathol. 2023; 38(11):1249-1256.

PMID: 37466108 DOI: 10.14670/HH-18-649.

Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.

Digifico E, Erreni M, Mannarino L, Marchini S, Ummarino A, Anfray C Front Immunol. 2023; 14:1116430.

PMID: 37398648 PMC: 10312076. DOI: 10.3389/fimmu.2023.1116430.

Diagnostic value of combination of biomarkers for malignant pleural mesothelioma: a systematic review and meta-analysis.

Zhu M, Lu Z, Guo H, Gu X, Wei D, Zhang Z Front Oncol. 2023; 13:1136049.

PMID: 37114132 PMC: 10126368. DOI: 10.3389/fonc.2023.1136049.

Identification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma.

Ferrari L, Iodice S, Cantone L, Dallari B, Dioni L, Bordini L Med Lav. 2022; 113(6):e2022052.

PMID: 36475505 PMC: 9766837. DOI: 10.23749/mdl.v113i6.13522.

References

Beyer H, Geschwindt R, Glover C, Tran L, Hellstrom I, Hellstrom K . MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem. 2007; 53(4):666-72. DOI: 10.1373/clinchem.2006.079327. View

Reddy K . MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015; 15:38. PMC: 4424445. DOI: 10.1186/s12935-015-0185-1. View

Sharova E, Grassi A, Marcer A, Ruggero K, Pinto F, Bassi P . A circulating miRNA assay as a first-line test for prostate cancer screening. Br J Cancer. 2016; 114(12):1362-6. PMC: 4984473. DOI: 10.1038/bjc.2016.151. View

Testa J, Cheung M, Pei J, Below J, Tan Y, Sementino E . Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011; 43(10):1022-5. PMC: 3184199. DOI: 10.1038/ng.912. View

Abdel-Rahman O . Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database. Strahlenther Onkol. 2017; 193(4):276-284. DOI: 10.1007/s00066-016-1092-7. View

Santarelli L, Staffolani S, Strafella E, Nocchi L, Manzella N, Grossi P . Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer. 2015; 90(3):457-64. DOI: 10.1016/j.lungcan.2015.09.021. View

Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad A, Vacek P . Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci U S A. 2006; 103(38):14128-33. PMC: 1599923. DOI: 10.1073/pnas.0604544103. View

Bianchi M, Beltrame M, Paonessa G . Specific recognition of cruciform DNA by nuclear protein HMG1. Science. 1989; 243(4894 Pt 1):1056-9. DOI: 10.1126/science.2922595. View

Creaney J, Olsen N, Brims F, Dick I, Musk A, de Klerk N . Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev. 2010; 19(9):2238-46. DOI: 10.1158/1055-9965.EPI-10-0346. View

10.

Bonotti A, Foddis R, Landi S, Melaiu O, De Santi C, Giusti L . A Novel Panel of Serum Biomarkers for MPM Diagnosis. Dis Markers. 2017; 2017:3510984. PMC: 5350384. DOI: 10.1155/2017/3510984. View

11.

Ivanov S, Ivanova A, Goparaju C, Chen Y, Beck A, Pass H . Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun. 2009; 382(3):514-8. DOI: 10.1016/j.bbrc.2009.03.042. View

12.

Chang K, Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996; 93(1):136-40. PMC: 40193. DOI: 10.1073/pnas.93.1.136. View

13.

Giusti L, Da Valle Y, Bonotti A, Donadio E, Ciregia F, Ventroni T . Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins. Proteomics Clin Appl. 2014; 8(3-4):258-68. DOI: 10.1002/prca.201300052. View

14.

Jube S, Rivera Z, Bianchi M, Powers A, Wang E, Pagano I . Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012; 72(13):3290-301. PMC: 3389268. DOI: 10.1158/0008-5472.CAN-11-3481. View

15.

Luo L, Shi H, Liang Q, Jiang J, Qin S, Deng J . Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med. 2009; 104(1):149-56. DOI: 10.1016/j.rmed.2009.05.017. View

16.

Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M . Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 2006; 97(9):928-32. PMC: 11158852. DOI: 10.1111/j.1349-7006.2006.00246.x. View

17.

Tajima K, Ohashi R, Sekido Y, Hida T, Nara T, Hashimoto M . Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 2010; 29(13):1941-51. DOI: 10.1038/onc.2009.478. View

18.

Griffiths-Jones S . miRBase: the microRNA sequence database. Methods Mol Biol. 2006; 342:129-38. DOI: 10.1385/1-59745-123-1:129. View

19.

Xu Y, Zheng M, Merritt R, Shrager J, Wakelee H, Kratzke R . miR-1 induces growth arrest and apoptosis in malignant mesothelioma. Chest. 2013; 144(5):1632-1643. PMC: 4694093. DOI: 10.1378/chest.12-2770. View

20.

Qi F, Okimoto G, Jube S, Napolitano A, Pass H, Laczko R . Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling. Am J Pathol. 2013; 183(5):1654-66. PMC: 3814524. DOI: 10.1016/j.ajpath.2013.07.029. View